Overview

* Coherus Q3 2025 sales miss analysts' expectations, adjusted net loss narrows less than expected

* LOQTORZI net revenue rises 12% over Q2 2025, driven by higher patient demand

* Company expands CHS-114 clinical program to include colorectal cancer

Outlook

* Coherus expects multiple data readouts from ongoing studies throughout 2026

* Company is expanding CHS-114 program to include colorectal cancer

* Coherus plans to combine LOQTORZI with internal candidates for new indications

Result Drivers

* LOQTORZI DEMAND - Higher patient demand and increased treatment duration drove a 12% increase in LOQTORZI net revenue over Q2 2025

* NCCN GUIDELINES - Revised NCCN guidelines granting LOQTORZI preferred status drive demand growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Sales Miss $11.57 $13.41

mln mln (5

Analysts

)

Q3 Miss -$38.90 -$33.54

Adjusted mln mln (5

Net Analysts

Income )

Q3 Net -$35.53

Income mln

Q3 -$44.33

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Coherus Oncology Inc ( CHRS ) is $6.00, about 73.9% above its November 5 closing price of $1.57

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)